SRC and actinic keratosis: Other promising c-Src inhibitors (in phase I or II, (Figure 2) are DGY-06–11633, eCF50634, Elzovantinib (TPX-0022)35, and Tirbanibulin, the latter targeting the Src substrate binding site36 and recently approved for the topical treatment of actinic keratosis.37